Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. .TMU Publications / 北醫出版品(教師升等著作 / 教學實踐 / 學位論文)
  3. .博碩士學位論文
  4. 109學年度
  5. Pembrolizumab合併化學治療用於轉移性非鱗狀非小細胞肺 癌治療之成本效益分析
 
  • Details
Options

Pembrolizumab合併化學治療用於轉移性非鱗狀非小細胞肺 癌治療之成本效益分析

Other Title
Cost-effectiveness analysis of pembrolizumab plus chemotherapy for metastatic non-squamous NSCLC
Type
thesis
Date Issued
2021-07-09
Author(s)
李瑋玲
Advisor
張偉嶠
Subjects
系所名稱:藥學系臨床藥學碩士在職專班
Description
學位別:碩士
語文別:中文
指導教授:張偉嶠
口試委員:蔡慧如 TSAI,HUI-JU;郭俊男 KUO,CHUN-NAN;張偉嶠 CHANG,WEI-CHIAO
電子論文連結:https://handle.ncl.edu.tw/11296/5x4zm9
URI
https://203.71.86.71/handle/123456789/61457

Copyright Notice

● The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use.

● Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner. Users must not use TMUIR for any illegal purposes.

● By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in this statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions.

● TMUIR is committed to protecting the interests of copyright owners. If you believe that any material on this website infringes copyright, please contact our staff at libirtmu@gmail.com, and we will remove the work from the repository.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback